HK1034455A1 - Oral pharmaceutical extended release dosage form. - Google Patents

Oral pharmaceutical extended release dosage form.

Info

Publication number
HK1034455A1
HK1034455A1 HK01105069A HK01105069A HK1034455A1 HK 1034455 A1 HK1034455 A1 HK 1034455A1 HK 01105069 A HK01105069 A HK 01105069A HK 01105069 A HK01105069 A HK 01105069A HK 1034455 A1 HK1034455 A1 HK 1034455A1
Authority
HK
Hong Kong
Prior art keywords
dosage form
extended release
release dosage
oral pharmaceutical
pharmaceutical extended
Prior art date
Application number
HK01105069A
Other languages
English (en)
Inventor
Per-Gunnar Karehill
Per Johan Lundberg
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HK1034455A1 publication Critical patent/HK1034455A1/xx

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2009—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Inorganic Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
HK01105069A 1997-12-22 2001-07-19 Oral pharmaceutical extended release dosage form. HK1034455A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
SE9704869A SE9704869D0 (sv) 1997-12-22 1997-12-22 New pharmaceutical formulaton II
PCT/SE1998/002368 WO1999032091A1 (en) 1997-12-22 1998-12-17 Oral pharmaceutical extended release dosage form

Publications (1)

Publication Number Publication Date
HK1034455A1 true HK1034455A1 (en) 2001-10-26

Family

ID=20409571

Family Applications (1)

Application Number Title Priority Date Filing Date
HK01105069A HK1034455A1 (en) 1997-12-22 2001-07-19 Oral pharmaceutical extended release dosage form.

Country Status (39)

Country Link
US (1) US6605303B1 (es)
EP (1) EP1043976B1 (es)
JP (1) JP4865945B2 (es)
KR (2) KR20060097069A (es)
CN (1) CN1171582C (es)
AR (1) AR017201A1 (es)
AT (1) ATE312602T1 (es)
AU (1) AU759634B2 (es)
BG (1) BG65028B1 (es)
BR (1) BR9814378A (es)
CA (1) CA2315261C (es)
CY (1) CY1106072T1 (es)
CZ (1) CZ299228B6 (es)
DE (1) DE69832816T2 (es)
DK (1) DK1043976T3 (es)
DZ (1) DZ2685A1 (es)
EE (1) EE04901B1 (es)
ES (1) ES2252875T3 (es)
HK (1) HK1034455A1 (es)
HR (1) HRP20000380B1 (es)
HU (1) HUP0101437A3 (es)
IL (2) IL136827A0 (es)
IS (1) IS5524A (es)
MA (1) MA26576A1 (es)
MY (1) MY126555A (es)
NO (1) NO20003218L (es)
NZ (1) NZ505127A (es)
PL (1) PL193776B1 (es)
RU (1) RU2214232C2 (es)
SA (1) SA99191077B1 (es)
SE (1) SE9704869D0 (es)
SK (1) SK284988B6 (es)
TN (1) TNSN98229A1 (es)
TR (1) TR200001981T2 (es)
TW (1) TWI249410B (es)
UA (1) UA69397C2 (es)
WO (1) WO1999032091A1 (es)
YU (1) YU36700A (es)
ZA (1) ZA9811239B (es)

Families Citing this family (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2220989T3 (es) * 1995-09-21 2004-12-16 Pharma Pass Ii Llc Nueva composicion que contiene benzimidazol labil al acido y procedimiento para su preparacion.
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
CA2310585C (en) 1997-12-08 2005-08-23 Byk Gulden Lomberg Chemische Fabrik Gmbh Novel administration form comprising an acid-labile active compound
FR2774288B1 (fr) * 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
US7029701B2 (en) * 2000-09-11 2006-04-18 Andrx Pharmaceuticals, Llc Composition for the treatment and prevention of ischemic events
AU2001211213A1 (en) * 2000-10-20 2002-04-29 Galephar M/F Stable oral formulation containing benzimidazole derivative
AU2002221939A1 (en) * 2000-12-07 2002-06-18 Byk Gulden Lomberg Chemische Fabrik G.M.B.H. Rapidly disintegrating tablet comprising an acid-labile active ingredient
JP4848101B2 (ja) * 2001-08-17 2011-12-28 株式会社フジモト・コーポレーション 徐放性マイクロペレット
CN100553625C (zh) 2002-04-09 2009-10-28 弗拉梅技术公司 活性成分微囊的口服混悬液
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
KR20050065550A (ko) 2002-09-26 2005-06-29 아스텔라스세이야쿠 가부시키가이샤 약물 흡수성 개선제
JP4493970B2 (ja) * 2002-10-16 2010-06-30 武田薬品工業株式会社 持続性製剤
MY148805A (en) * 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
CA2771725C (en) 2002-10-16 2015-08-18 Takeda Pharmaceutical Company Limited Solid preparation comprising a non-toxic base and a proton pump inhibitor
JP4933033B2 (ja) * 2003-03-17 2012-05-16 武田薬品工業株式会社 放出制御組成物
CA2519208A1 (en) 2003-03-17 2004-09-30 Takeda Pharmaceutical Company Limited Controlled release composition
PE20050150A1 (es) * 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
CL2004000983A1 (es) * 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
WO2005012289A1 (en) * 2003-07-17 2005-02-10 Altana Pharma Ag Novel salt of (r) - pantoprazole
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
TWI372066B (en) * 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
FR2861990B1 (fr) * 2003-11-10 2006-02-10 Nouveaux Produits Pharma Comprimes faiblement doses a reseau de polymeres
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
CA2469427A1 (en) * 2004-06-01 2005-12-01 Pharmascience Inc. Dry mixed dosage form containing benzimidazole derivatives
AU2005264864B2 (en) 2004-06-16 2011-08-11 Takeda Pharmaceutical Company Limited Multiple PPI dosage form
US20090124702A1 (en) * 2005-01-25 2009-05-14 Pechetti Siva Satya Krishna Babu Pharmaceutical Compositions of Metformin
KR100591142B1 (ko) * 2005-11-04 2006-06-20 지엘팜텍 주식회사 파록세틴을 활성물질로 함유하는 장용성 서방형 정제
DE102005060393A1 (de) * 2005-12-16 2007-06-21 Add Advanced Drug Delivery Technologies Ltd. Orales Präparat mit kontrollierter Freisetzung
EP1967183A4 (en) * 2005-12-28 2011-02-23 Takeda Pharmaceutical SOLID PREPARATION WITH CONTROLLED RELEASE
JP2009538901A (ja) * 2006-06-01 2009-11-12 デクセル ファーマ テクノロジーズ エルティーディー． 複式ユニット製薬的製剤
US20080181932A1 (en) * 2007-01-30 2008-07-31 Drugtech Corporation Compositions for oral delivery of pharmaceuticals
WO2008112388A1 (en) * 2007-03-14 2008-09-18 Drugtech Corporation Spatial arrangement of particles in a drinking device for oral delivery of pharmaceuticals
RU2010119041A (ru) * 2007-10-12 2011-11-20 Такеда Фармасьютикалз Норт Америка, Инк. (Us) Способы лечения нарушений желудочно-кишечного тракта, независимого от потребления пищи
US8945622B2 (en) 2009-03-09 2015-02-03 Council Of Scientific And Industrial Research Sustained release composition of therapeutic agent
US20140127296A1 (en) * 2012-11-05 2014-05-08 Kenneth John Tibbs Pharmaceutical preparation and method for treatment of diabetes
ES2744406T3 (es) * 2013-02-13 2020-02-25 Redhill Biopharma Ltd Composiciones farmacéuticas para el tratamiento de helicobacter pylori
CN104721185A (zh) * 2013-12-21 2015-06-24 辰欣药业股份有限公司 一种提高埃索美拉唑钠稳定性的方法
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
WO2017145146A1 (en) 2016-02-25 2017-08-31 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
US10729735B1 (en) 2016-09-14 2020-08-04 Phoenix Biotechnology, Inc. Method and compostitions for treating coronavirus infection
US11878011B2 (en) 2020-05-07 2024-01-23 Redhill Biopharma Ltd. Method for eradicating Helicobacter pylori infection in patients regardless of body mass index

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE7804231L (sv) * 1978-04-14 1979-10-15 Haessle Ab Magsyrasekretionsmedel
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
AU4640985A (en) * 1984-08-31 1986-03-06 Nippon Chemiphar Co. Ltd. Benzimidazole derivatives
US5229181A (en) * 1990-10-30 1993-07-20 Amber Technologies Tubular knit cleanroom wiper
TW209174B (es) 1991-04-19 1993-07-11 Takeda Pharm Industry Co Ltd
IT1251153B (it) 1991-08-06 1995-05-04 Vectorpharma Int Composizioni farmaceutiche solide per somministrazione orale aventi proungata residenza gastrica
SK281042B6 (sk) * 1992-09-18 2000-11-07 Yamanouchi Pharmaceutical Co., Ltd Prípravok hydrogélového typu s ustáleným uvoľňovaním
JPH06199657A (ja) * 1992-12-10 1994-07-19 Sumitomo Pharmaceut Co Ltd 徐放性製剤
SE9301830D0 (sv) * 1993-05-28 1993-05-28 Ab Astra New compounds
JPH07330629A (ja) * 1994-06-02 1995-12-19 Nippon Shokubai Co Ltd 徐放性製剤
KR100384960B1 (ko) * 1994-07-08 2003-08-21 아스트라제네카 악티에볼라그 다단위정제투여형i
BR9508261A (pt) * 1994-07-08 1997-12-23 Astra Ab Formulação oral entericamente revestida uso da mesma processo para preparer a formulação inibir a secreção de ácido gástrico em mamíferos e no ser humano e tratar doenças relacionadas ao ácido gástrico em maníferos e no ser humano e pacote de empola de pressão transversal
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
US6132768A (en) 1995-07-05 2000-10-17 Byk Gulden Lomberg Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for reversible proton pump inhibitors
US5945124A (en) * 1995-07-05 1999-08-31 Byk Gulden Chemische Fabrik Gmbh Oral pharmaceutical composition with delayed release of active ingredient for pantoprazole
SE9600071D0 (sv) * 1996-01-08 1996-01-08 Astra Ab New oral formulation of two active ingredients I
AU3290397A (en) 1996-06-10 1998-01-07 Depomed, Inc. Gastric-retentive oral controlled drug delivery system with enhanced retention properties
SE9602442D0 (sv) * 1996-06-20 1996-06-20 Astra Ab Administration of pharmaceuticals
DE19626045C2 (de) * 1996-06-28 1998-12-03 Klinge Co Chem Pharm Fab Stabile Arzneiform zur oralen Verabreichung, welche Omeprazol als aktiven Wirkstoff enthält, sowie Verfahren zur Herstellung derselben
US7016717B2 (en) * 2002-07-05 2006-03-21 The Regents Of The University Of California Near-infrared spectroscopic tissue imaging for medical applications
ITPD20050230A1 (it) * 2005-07-28 2007-01-29 Marcato Spa Macchina ad uso domestico per la estrusione di paste alimentari fresche

Also Published As

Publication number Publication date
CZ20002314A3 (cs) 2000-11-15
WO1999032091A1 (en) 1999-07-01
HRP20000380A2 (en) 2001-06-30
AR017201A1 (es) 2001-08-22
KR100755154B1 (ko) 2007-09-04
EE04901B1 (et) 2007-10-15
KR20060097069A (ko) 2006-09-13
TR200001981T2 (tr) 2000-11-21
PL341428A1 (en) 2001-04-09
IS5524A (is) 2000-06-08
AU759634B2 (en) 2003-04-17
JP2001526211A (ja) 2001-12-18
JP4865945B2 (ja) 2012-02-01
DE69832816T2 (de) 2006-08-31
DZ2685A1 (fr) 2003-03-29
NO20003218L (no) 2000-08-22
BG104620A (en) 2001-04-30
ZA9811239B (en) 1999-06-22
SK8072000A3 (en) 2001-01-18
MY126555A (en) 2006-10-31
NZ505127A (en) 2003-02-28
CA2315261C (en) 2008-02-12
CY1106072T1 (el) 2011-06-08
ES2252875T3 (es) 2006-05-16
EP1043976B1 (en) 2005-12-14
HUP0101437A2 (hu) 2001-10-28
SE9704869D0 (sv) 1997-12-22
IL136827A0 (en) 2001-06-14
MA26576A1 (fr) 2004-12-20
US6605303B1 (en) 2003-08-12
PL193776B1 (pl) 2007-03-30
BR9814378A (pt) 2000-10-10
HUP0101437A3 (en) 2003-01-28
CA2315261A1 (en) 1999-07-01
ATE312602T1 (de) 2005-12-15
KR20010033428A (ko) 2001-04-25
DE69832816D1 (de) 2006-01-19
IL136827A (en) 2007-05-15
TWI249410B (en) 2006-02-21
EP1043976A1 (en) 2000-10-18
BG65028B1 (bg) 2006-12-29
SA99191077B1 (ar) 2006-07-11
TNSN98229A1 (fr) 2005-03-15
EE200000383A (et) 2001-12-17
CN1284866A (zh) 2001-02-21
CN1171582C (zh) 2004-10-20
YU36700A (sh) 2003-01-31
SK284988B6 (sk) 2006-04-06
CZ299228B6 (cs) 2008-05-21
NO20003218D0 (no) 2000-06-21
RU2214232C2 (ru) 2003-10-20
AU1991299A (en) 1999-07-12
HRP20000380B1 (en) 2007-08-31
DK1043976T3 (da) 2006-03-20
UA69397C2 (uk) 2004-09-15

Similar Documents

Publication Publication Date Title
HK1034455A1 (en) Oral pharmaceutical extended release dosage form.
EG23875A (en) Oral pharmaceutical pulsed release dosage form
ZA987551B (en) Solid pharmaceutical dosage forms
ZA200007714B (en) Extended release oral dosage composition.
ZA200202480B (en) Oral dosage forms.
AU7375598A (en) Stable oral pharmaceutical dosage forms
IL149224A0 (en) Hydrogen-driven drug dosage form
GB9613470D0 (en) Small solid oral dosage form
HUP0203204A3 (en) Oral dosage forms
ZA200007715B (en) Stable extended release oral dosage composition.
AU6089200A (en) Rapid immediate release oral dosage form
ZA993338B (en) Pharmaceutical formulations.
IL117041A0 (en) Oral pharmaceutical dosage form
ZA985364B (en) Pharmaceutical formulations containing voriconazole.
MXPA01012478A (es) Formulaciones farmaceuticas mejoradas.
IL138192A0 (en) Controlled release oral dosage forms
ZA983169B (en) Pharmaceutical dosage units
ZA982073B (en) Pharmaceutical preparation
HK1040488A1 (en) Pharmaceutical formulations.
EP1173216A4 (en) PHARMACEUTICAL FORMULATIONS
ZA200108206B (en) Oral pharmaceutical ibuprofen suspension.
SI1043976T1 (sl) Oralna farmacevtska dozirna oblika s podaljsanim sproscanjem
SI1043977T1 (en) Oral pharmaceutical pulsed release dosage form
GB9712357D0 (en) Pharmaceutical dosage form
IL120172A0 (en) Pharmaceutical dosage form

Legal Events

Date Code Title Description
PC Patent ceased (i.e. patent has lapsed due to the failure to pay the renewal fee)

Effective date: 20141217